secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer
--------------------------------------------------------------------------------

- Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).
- Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).
- Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).
- Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.
- Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/0001193125-26-007037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/psnl-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer